vs
Side-by-side financial comparison of F5, Inc. (FFIV) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $811.7M, roughly 1.8× F5, Inc.). F5, Inc. runs the higher net margin — 18.2% vs 4.4%, a 13.8% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 11.0%). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 8.0%).
F5, Inc. is an American technology company specializing in application security, multi-cloud management, online fraud prevention, application delivery networking (ADN), application availability and performance, and network security, access, and authorization.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
FFIV vs ONC — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $811.7M | $1.5B |
| Net Profit | $148.0M | $66.5M |
| Gross Margin | 81.4% | 90.5% |
| Operating Margin | 22.1% | 12.4% |
| Net Margin | 18.2% | 4.4% |
| Revenue YoY | 11.0% | 32.8% |
| Net Profit YoY | 1.5% | 143.8% |
| EPS (diluted) | $2.58 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $811.7M | — | ||
| Q4 25 | $822.5M | $1.5B | ||
| Q3 25 | $810.1M | $1.4B | ||
| Q2 25 | $780.4M | $1.3B | ||
| Q1 25 | $731.1M | $1.1B | ||
| Q4 24 | $766.5M | $1.1B | ||
| Q3 24 | $746.7M | $1.0B | ||
| Q2 24 | $695.5M | $929.2M |
| Q1 26 | $148.0M | — | ||
| Q4 25 | $180.1M | $66.5M | ||
| Q3 25 | $190.5M | $124.8M | ||
| Q2 25 | $189.9M | $94.3M | ||
| Q1 25 | $145.5M | $1.3M | ||
| Q4 24 | $166.4M | $-151.9M | ||
| Q3 24 | $165.3M | $-121.3M | ||
| Q2 24 | $144.1M | $-120.4M |
| Q1 26 | 81.4% | — | ||
| Q4 25 | 81.5% | 90.5% | ||
| Q3 25 | 82.2% | 86.1% | ||
| Q2 25 | 81.0% | 87.5% | ||
| Q1 25 | 80.7% | 85.2% | ||
| Q4 24 | 81.7% | 85.8% | ||
| Q3 24 | 80.8% | 83.0% | ||
| Q2 24 | 80.4% | 85.1% |
| Q1 26 | 22.1% | — | ||
| Q4 25 | 26.0% | 12.4% | ||
| Q3 25 | 25.4% | 11.5% | ||
| Q2 25 | 25.2% | 6.7% | ||
| Q1 25 | 21.7% | 1.0% | ||
| Q4 24 | 26.8% | -7.0% | ||
| Q3 24 | 25.6% | -12.0% | ||
| Q2 24 | 23.4% | -11.5% |
| Q1 26 | 18.2% | — | ||
| Q4 25 | 21.9% | 4.4% | ||
| Q3 25 | 23.5% | 8.8% | ||
| Q2 25 | 24.3% | 7.2% | ||
| Q1 25 | 19.9% | 0.1% | ||
| Q4 24 | 21.7% | -13.5% | ||
| Q3 24 | 22.1% | -12.1% | ||
| Q2 24 | 20.7% | -13.0% |
| Q1 26 | $2.58 | — | ||
| Q4 25 | $3.10 | $0.05 | ||
| Q3 25 | $3.25 | $0.08 | ||
| Q2 25 | $3.25 | $0.06 | ||
| Q1 25 | $2.48 | $0.00 | ||
| Q4 24 | $2.82 | $-0.10 | ||
| Q3 24 | $2.79 | $-0.09 | ||
| Q2 24 | $2.44 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $4.5B |
| Total DebtLower is stronger | — | $836.4M |
| Stockholders' EquityBook value | $3.6B | $4.4B |
| Total Assets | $6.5B | $8.2B |
| Debt / EquityLower = less leverage | — | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.2B | $4.5B | ||
| Q3 25 | $1.3B | $4.0B | ||
| Q2 25 | $1.4B | $2.8B | ||
| Q1 25 | $1.3B | $2.5B | ||
| Q4 24 | $1.2B | $2.6B | ||
| Q3 24 | $1.1B | $2.7B | ||
| Q2 24 | $935.6M | $2.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | $836.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.5B | $4.4B | ||
| Q3 25 | $3.6B | $4.1B | ||
| Q2 25 | $3.5B | $3.8B | ||
| Q1 25 | $3.3B | $3.5B | ||
| Q4 24 | $3.2B | $3.3B | ||
| Q3 24 | $3.1B | $3.4B | ||
| Q2 24 | $3.0B | $3.4B |
| Q1 26 | $6.5B | — | ||
| Q4 25 | $6.3B | $8.2B | ||
| Q3 25 | $6.3B | $7.6B | ||
| Q2 25 | $6.1B | $6.3B | ||
| Q1 25 | $5.9B | $5.8B | ||
| Q4 24 | $5.9B | $5.9B | ||
| Q3 24 | $5.6B | $5.8B | ||
| Q2 24 | $5.4B | $5.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $525.1M | $417.3M |
| Free Cash FlowOCF − Capex | — | $379.8M |
| FCF MarginFCF / Revenue | — | 25.4% |
| Capex IntensityCapex / Revenue | — | 2.5% |
| Cash ConversionOCF / Net Profit | 3.55× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $525.1M | — | ||
| Q4 25 | $159.2M | $417.3M | ||
| Q3 25 | $208.1M | $402.6M | ||
| Q2 25 | $282.2M | $263.6M | ||
| Q1 25 | $256.6M | $44.1M | ||
| Q4 24 | $202.8M | $75.2M | ||
| Q3 24 | $246.5M | $188.4M | ||
| Q2 24 | $159.0M | $-95.6M |
| Q1 26 | — | — | ||
| Q4 25 | $149.5M | $379.8M | ||
| Q3 25 | $191.9M | $354.5M | ||
| Q2 25 | $273.7M | $219.8M | ||
| Q1 25 | $246.1M | $-12.3M | ||
| Q4 24 | $194.7M | $-17.3M | ||
| Q3 24 | $240.4M | $54.7M | ||
| Q2 24 | $153.1M | $-205.5M |
| Q1 26 | — | — | ||
| Q4 25 | 18.2% | 25.4% | ||
| Q3 25 | 23.7% | 25.1% | ||
| Q2 25 | 35.1% | 16.7% | ||
| Q1 25 | 33.7% | -1.1% | ||
| Q4 24 | 25.4% | -1.5% | ||
| Q3 24 | 32.2% | 5.5% | ||
| Q2 24 | 22.0% | -22.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 2.5% | ||
| Q3 25 | 2.0% | 3.4% | ||
| Q2 25 | 1.1% | 3.3% | ||
| Q1 25 | 1.4% | 5.0% | ||
| Q4 24 | 1.1% | 8.2% | ||
| Q3 24 | 0.8% | 13.3% | ||
| Q2 24 | 0.8% | 11.8% |
| Q1 26 | 3.55× | — | ||
| Q4 25 | 0.88× | 6.28× | ||
| Q3 25 | 1.09× | 3.22× | ||
| Q2 25 | 1.49× | 2.79× | ||
| Q1 25 | 1.76× | 34.71× | ||
| Q4 24 | 1.22× | — | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
